Literature DB >> 21120643

Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor.

B Nasilowska-Adamska1, A Perkowska-Ptasinska, A Tomaszewska, A Serwacka, B Marianska.   

Abstract

Following on from the recently published articles reported side effects occurring due to donation of stem cells, we describe a case of a donor with transient, biopsy-proved acute focal segmental proliferative glomerulonephritis (GN) due to peripheral blood stem cells (PBSC) mobilization with granulocyte colony-stimulating factor (G-CSF). A 44-year-old woman with no relevant past medical history suffering from obesity and hypertension well controlled with metoprolol without hypertensive retinopathy was admitted to our hospital as a donor of PBSC. She received G-CSF subcutaneously-filgrastim (Amgen)-at a dose of 5 microg/kg twice a day for 6 days. The macroscopic hematuria and proteinuria occurred on 5th day of G-CSF administration. Due to mobilization and collection of stem cells, proteinuria was becoming more intense and reached the nephrotic range. The immunological, infectious, urological and gynecological causes of such complication were excluded. The final histological recognition was early stage of focal segmental proliferative GN. To our knowledge this a first report of GN in a donor due to mobilization of PBSC confirmed with renal biopsy. These findings suggest that filgrastim may induce transient urinary excretion of protein and hematuria in PBSC donors as the symptoms of acute GN without adversely affecting renal function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120643     DOI: 10.1007/s12185-010-0730-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

1.  Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim).

Authors:  M Sotomatsu; T Kanazawa; C Ogawa; T Watanabe; A Morikawa
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Differences between graft product and donor side effects following bone marrow or stem cell donation.

Authors:  G Favre; M Beksaç; A Bacigalupo; T Ruutu; A Nagler; E Gluckman; N Russell; J Apperley; J Szer; K Bradstock; A Buzyn; J Matcham; A Gratwohl; N Schmitz
Journal:  Bone Marrow Transplant       Date:  2003-11       Impact factor: 5.483

Review 3.  Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation.

Authors:  Nicolaus Kröger; Axel R Zander
Journal:  Leuk Lymphoma       Date:  2002-07

4.  Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor.

Authors:  A Falanga; M Marchetti; V Evangelista; S Manarini; E Oldani; S Giovanelli; M Galbusera; C Cerletti; T Barbui
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

5.  Severe events in donors after allogeneic hematopoietic stem cell donation.

Authors:  Joerg Halter; Yoshihisa Kodera; Alvaro Urbano Ispizua; Hildegard T Greinix; Norbert Schmitz; Geneviève Favre; Helen Baldomero; Dietger Niederwieser; Jane F Apperley; Alois Gratwohl
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

Review 6.  Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Tammy E Cottle; Carol J Fier; Audrey Anna Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Melvin H Freedman; George Kannourakis; Sally E Kinsey; Robert Davis; Debra Scarlata; Beate Schwinzer; Cornelia Zeidler; Karl Welte
Journal:  Am J Hematol       Date:  2003-02       Impact factor: 10.047

Review 7.  Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.

Authors:  C C Tigue; J M McKoy; A M Evens; S M Trifilio; M S Tallman; C L Bennett
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

Review 8.  Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.

Authors:  John P Miller; Elizabeth H Perry; Thomas H Price; Charles D Bolan; Chatchada Karanes; Theresa M Boyd; Pintip Chitphakdithai; Roberta J King
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

Review 9.  Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges.

Authors:  Paolo Anderlini; Richard E Champlin
Journal:  Blood       Date:  2007-12-05       Impact factor: 22.113

  9 in total
  7 in total

1.  Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening.

Authors:  J B L Lee; A Billen; R N Lown; M N Potter; C F Craddock; H de Lavallade; B E Shaw; C C Sharpe
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation.

Authors:  S Bräuninger; K Thorausch; B Luxembourg; M Schulz; K U Chow; E Seifried; H Bonig
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

3.  Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Authors:  Ibrahim Batal; Glen S Markowitz; Waichi Wong; Rupali Avasare; Markus Y Mapara; Gerald B Appel; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2016-05-04       Impact factor: 10.121

4.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

5.  G-CSF-induced ANCA associated glomerulonephritis in the presence of silent membranous "full house nephropathy" in an altruistic bone marrow donor.

Authors:  Avital Angel Korman; Adi Leiba; Yonatan Edel; Vladimir Rapoport; Ana Tobar; Merav Leiba
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  Relapsing acute kidney injury associated with pegfilgrastim.

Authors:  Swati Arora; Arpit Bhargava; Katherine Jasnosz; Barbara Clark
Journal:  Case Rep Nephrol Urol       Date:  2012-11-21

7.  Development of membranoproliferative glomerulonephritis-like glomerulopathy in a patient with neutrophilia resulting from endogenous granulocyte-colony stimulating factor overproduction: a case report.

Authors:  Seigo Ito; Takahiro Uchida; Naoki Oshima; Takashi Oda; Hiroo Kumagai
Journal:  BMC Nephrol       Date:  2018-10-04       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.